

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):


- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.


Capillary Electrophoresis with Laser Induce Fluorescence analysis of C2B8 and other oligosaccharides.

Before enzyme treatment.




A

After treatment with β -galactosidase.



B


After treatment with β -galactosidase and N-acetyl β -D-glucosaminidase.



C

1


Binding of C1q to C2B8 samples pre-bound to WIL2-S cells



© 2003 Biomedical Materials Group

2

Comparison of CDC Bioactivity of IgG Glycoforms




Q591E386244 A102098

3

Fig. 4

Analysis of N-linked Oligosaccharides of
C2B8 by Capillary Electrophoresis



5

Fig.

Galactosylation of anti-VEGF




Fig. 6

Galactosylation of RhuMab-E25




Fig 7




FIGURE 8 frame 6





Fig.

9



Reduced

Fig.
10
Far UV CD Spectra of C₂B8 Antibody Variants




Fig. 10B
Near UV Spectra of C2B8 Antibody Variants





Fig.
||



Moles Galactose
Heavy Chain

Fig. 12

Correlation Of Bioactivity And Galactose Content In rituximab

